Evidence map›Paper›PMID 38714500›Full record

ReviewExpert opinion on therapeutic targets2024

Current challenges in the discovery of treatments against Mayaro fever.

Rafael Elias Marques, Jacqueline Farinha Shimizu, Maurício Lacerda Nogueira, Nikos Vasilakis

Abstract readReview
In one paragraph

Review in Expert opinion on therapeutic targets, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Rafael Elias MarquesBrazilian Biosciences National Laboratory - LNBio, Brazilian Center for Research in Energy and Materials - CNPEM, Campinas, São Paulo, Brazil.
Jacqueline Farinha ShimizuBrazilian Biosciences National Laboratory - LNBio, Brazilian Center for Research in Energy and Materials - CNPEM, Campinas, São Paulo, Brazil.
Maurício Lacerda NogueiraLaboratórios de Pesquisas em Virologia, Departamento de Doenças Dermatológicas, Infecciosas e Parasitá-rias, Faculdade de Medicina de São José do Rio Preto, São José do Rio Preto, SP, Brazil.
Nikos VasilakisDepartment of Pathology and Center for Research in Vector-Borne and Zoonotic Diseases, University of Texas Medical Branch, Galveston, TX, USA.

Funding

Coordinating Research on Emerging Arboviral Threats Encompassing the Neotropics II (CREATE-NEO II)U01AI151807 · NIAID · UNIVERSITY OF TEXAS MED BR GALVESTON · PI Kathryn Alyce Hanley, MAURICIO Lacerda NOGUEIRA · 2020 to 2026
$9.8M
NIAID NIH HHS U01 AI151807
6 · The paper itself

Abstract

introductionMayaro fever is an emerging viral disease that manifests as an acute febrile illness. The disease is self-limiting, however joint pain can persist for months leading to chronic arthralgia. There is no specific treatment available, which ultimately leads to socioeconomic losses in populations at risk as well as strains to the public health systems. AREAS COVERED: We reviewed the candidate treatments proposed for Mayaro virus (MAYV) infection and disease, including antiviral compounds targeting viral or host mechanisms, and pathways involved in disease development and pathogenicity. We assessed compound screening technologies and experimental infection models used in these studies and indicated the advantages and limitations of available technologies and intended therapeutic strategies. EXPERT OPINION: Although several compounds have been suggested as candidate treatments against MAYV infection, notably those with antiviral activity, most compounds were assessed only

Indexed as

Alphavirus InfectionsAntiviral AgentsDrug DiscoveryAlphavirusAnimalsArthralgiaDisease Models, AnimalDrug DevelopmentHumansMolecular Targeted TherapyAntiviral AgentsAntiviral compoundsarthritogenic diseasecandidate treatmentscompound screening technologiesimmunopathogenesisinfection modelsmayaro virus

Identifiers

PMID38714500
PMCPMC11189740

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.